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Abstract
Background: Pathways in biological system often cooperate with each other to function.
Changes of interactions among pathways tightly associate with alterations in the properties and
functions of the cell and hence alterations in the phenotype. So, the pathway interactions and
especially their changes over time corresponding to specific phenotype are critical to understanding
cell functions and phenotypic plasticity.
Methods: With prior-defined pathways and incorporated protein-protein interaction (PPI) data,
we counted PPIs between corresponding gene sets of each pair of distinct pathways to construct a
comprehensive pathway network. Then we proposed a novel concept, characteristic sub pathway
network (CSPN), to realize the phenotype-specific pathway interactions. By adding gene
expression data regarding a given phenotype, angiogenesis, active PPIs corresponding to stimulation
of interleukin-1 (IL-1) and tumor necrosis factor a (TNF-a) on human umbilical vein endothelial
cells (HUVECs) respectively were derived. Two kinds of CSPN, namely the static or the dynamic
CSPN, were detected by counting active PPIs.
Results: A comprehensive pathway network containing 37 signalling pathways as nodes and 263
pathwayinteractionswereobtained.Twophenotype-specificCSPNsforangiogenesis,corresponding
to stimulation of IL-1 and TNF-a on HUVEC respectively, were addressed. From phenotype-specific
CSPNs,astaticCSPNinvolvinginteractionsamongBcellreceptor,Tcellreceptor,Toll-likereceptor,
MAPK,VEGF,andErbBsignallingpathways,andadynamicCSPNinvolvinginteractionsamongTGF-b,
Wnt,p53signallingpathwaysandcellcyclepathway,weredetectedforangiogenesisonHUVECafter
stimulation of IL-1 and TNF-a respectively. We inferred that, in certain case, the static CSPN
maintains related basic functions of the cells, whereas the dynamic CSPN manifests the cells’ plastic
responses to stimulus and therefore reflects the cells’ phenotypic plasticity.
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Open AccessConclusion: The comprehensive pathway network helps us realize the cooperative behaviours
among pathways. Moreover, two kinds of potential CSPNs found in this work, the static CSPN and
the dynamic CSPN, are helpful to deeply understand the specific function of HUVEC and its
phenotypic plasticity in regard to angiogenesis.
Background
The advent of high-throughput technologies has encour-
aged the appearance of a lot of analysing tools, which
were intended for interpreting gene expression data and
extracting biological insight. No longer being limited to
produce a ranked list of differentially expressed genes,
most of those analysing tools are designed from the
perspective of system biology and identify gene sets over-
represented in biological processes [1-6]. A gene set
could be a group of genes corresponding to a pathway or
a group of genes sharing the same Gene Ontology term.
Gene Set Enrichment Analysis [2] and other similar tools
are capable to determine pathways which are enriched in
the gene list of specific phenotype. Yet these methods fail
to furnish the interactions among pathways, not to
mention changes of the pathway interactions. Actually,
the interactions among pathways are helpful for better
understanding of cooperation of pathways which are
critical in the functioning of each related pathway.
Likewise, changes of the pathway interactions are
important for comprehending alterations in the proper-
ties and functions of the cell and therefore the
phenotypic plasticity, which is cell’s ability to alter
phenotype in response to specific environmental stimu-
lus [1,7,8].
In recent years, several efforts have been made to
surmount the limitation of those methods. Global
pathway crosstalk network (GPCN) based method [5]
calculates possible crosstalks among pathways and then
analyzes microarray data based on these crosstalks to
infer sub networks where enriched pathways tied closely
to each other as potential modules. Pathway dependency
structure (PDS) based method [6], in the first place,
determines pathways involved in two transitions of
cancer progression, and successively constructs a path-
way network for each transition according to the
interdependences of pathways. However, there are still
problems to overcome. (i) Although whether interac-
tions among pathways exist could be determined and
p-values could be given, the types of interactions are lack
in consideration and discussion. GPCN based method
did not consider sharing components [5], which means
that different pathways have common components and
interact with each other via them, while embedded
pathway network based method just considered sharing
components [9]. (ii) Generally, the components and
their interrelations within distinct pathways are manu-
ally collected from literature or other resources by expert
curators. Consequently, the importance of context that
some genes in specific pathway may be not involved
under particular condition must be considered. How-
ever, GPCN based method and PDS based method both
did not take into account this importance, though gene
level analysis of the latter considered it. As a result, these
two methods both missed interactions between pairs of
pathways at least one of which was not enriched [5,6].
And GPCN based method even missed interactions
which were significant in current case but insignificant
in comprehensive pathway network [5]. (iii) The
alteration of pathway interactions remains to be studied.
GPCN based method did not consider the alteration of
interactions [5]. And since PDS based method had no
whole possible interdependence network as the base of
analysis, nodes of networks constructed with this
method were so different that a big part of the real
alteration of interactions among involved pathways was
still concealed [6].
Actually, from current literatures, we found that pathway
may interact with one other by means of five ways:
sharing components [9], components physically inter-
acting with counterparts from the other pathway [9,10],
components being enzymatic targets of the other path-
way [10], components relating with components of the
other pathway via transcription [10], one pathway
generating signal which modulates or competes for a
key modulator or mediator of the other [10]. At length,
the first way means distinct pathways have common
components like genes or gene products and these shared
components produce interactions among pathways; the
second way depends on the physical protein-protein
interactions (PPIs) like binding and phosphorylation; the
third way could be reflected by the indirect PPI by two
successive enzymes in the metabolic pathway; the fourth
way could be represented by indirect PPIs between
transcriptional factors and transcribed gene products,
which reflect the corresponding gene regulation; the fifth
way involves all kinds of PPIs mentioned above.
So we incorporated distinct PPIs to derive interactions
among pathways. By counting PPIs between correspond-
ing gene sets of each pair of pathways, pathway
interactions could be assessed. Furthermore, since no
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PPI works under any condition, we incorporated gene
expression data to infer active PPIs, which have at least
one differentially expressed corresponding gene, in
certain case for distinct phenotype, such as angiogenesis.
And then we constructed phenotype-specific pathway
networks with the derived sets of active PPIs. Two sub
phenotype-specific pathway networks were detected as
angiogenesis-related characteristic sub pathway networks
(CSPNs) to manifest the specific function of the cell and
its phenotypic plasticity with regard to angiogenesis.
Angiogenesis studied in this work, as the process of new
blood vessel formation, is fundamental to reproduction,
development, and repair. Strictly regulated by many
inducers and inhibitors, it could be aroused when the
local equilibrium between them is changed. At the
phenotype level, angiogenesis is critical to inflammatory
responses and cancers [11]. In our work, two series of
gene expression data were used to infer CSPNs for
angiogenesis. Those data are about human umbilical
vein endothelial cells (HUVEC) after stimulations of
Interleukin-1 (IL-1) and tumor necrosis factor a (TNF-a),
both are known proangiogenic factors. Actually, after
beingtreatedwithdifferentproangiogenicfactorsorsame
factor but with various dosages, some pathway interac-
tions of the cell keep constant, others alter. Those
constant interactions are likely required immediately
and continually by the cell for basic function in regard to
particular stimulus like IL-1 and TNF-a for angiogenesis,
whereas those changed interactions are probably reflect
the phenotype plasticity concerning specific stimulus
such as IL-1 and TNF-a for angiogenesis.
Methods
Preparation of PPI data
To complement substantial information loss of restrict-
ing the pathway interactions to those by means of
physical PPIs like binding or phosphorylation, we
considered all the five kinds of pathway interactions.
We gathered the PPI data from Human Protein Reference
Database [12] and Kyoto Encyclopedia of Genes and
Genomes [13]. HPRD PPIs are mainly physical PPIs. The
generalized PPI in KEGG includes three types of
interactions: PPI by two successive enzymes in a
known pathway, PPI like binding or phosphorylation,
PPI between transcription factor and transcribed gene
product via gene expression, which actually reflects the
gene expression regulation between transcription factor
and its regulated gene [13].
Preparation of pathway data
Generally, established pathways from various databases
can be approximately divided into three categories:
metabolic pathways, signalling pathways, and pathways
of specific diseases or drugs [9]. At length, metabolic
pathways focus on the metabolism and metabolic
products of cells, having much less relations with PPI.
In contrast, signalling pathways mainly involve genes
and gene products. Also, the environmental information
processing is of biological essence to cells, while the
cellular information processing is of clinical conse-
quence: a breakdown in it underlies many diseases
[14]. In KEGG, pathways designed for the study of
specific diseases are often integrated from some other
pathways in former two categories, and pathways from
‘Drug development’ category are drug structure maps on
the structure relationships of drugs. Thus, considering
the ways in which pathway interacts with each other are
of proteins, we gathered 48 human pathways from
‘Environmental Information Processing’ and ‘Cellular
Processes’ categories of KEGG as the reference of path-
ways to elucidate the cooperation of pathways in cells
and cells’ phenotypic plasticity.
Construction of pathway network and detection of CSPNs
The workflow for constructing pathway network was
illustrated in Figure 1 and depicted as follows. (i)
Generate the PPI network with 57092 interactions
among 10204 proteins, which are gathered from
HPRD and KEGG. (ii) Generate the reference of
pathways from ‘Environmental Information Processing’
and ‘Cellular Processes’ categories of KEGG Pathway
Maps. (iii) Exploiting GeneMerge method [15], produce
the pathways set by identifying pathways, which were
enriched in the involved genes list of the PPI network
from the reference of pathways. (iv) Option: incorpo-
rate gene expression data to infer active PPIs. Under
certain condition, only a part of the PPIs could be
regarded as active interactions. We obtain the set of
active PPIs with Microarray data. Then, the phenotype-
specific pathway network could be constructed.
(v) Count (active) PPIs between each pair of distinct
pathways. A common gene between any two pathways
will be treated as two discrete genes, which interact with
same genes as that original common gene, belonging to
these two pathways respectively. But the relationship of
sharing itself is not considered as interaction. (vi)Assess
the effect of PPI network itself as background to the
number of PPIs between any pair of pathways. Firstly,
those enriched pathways are permuted by randomly
exchanging two distinct genes from two different
pathways for 100,000 times. Both exchanged genes
should interact with at least one gene. Secondly,
perform step (iv) to count PPIs between each pair of
pathways after permutation. This whole pipeline is
repeated for 1,000 times. And then the background
distribution of the number of PPIs between each pair of
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way to permute pathways: just exchange pairs of genes
which have the similar number of PPIs. And the results
of these two approaches in step (iv) are approximately
same. (vii) Determine which of the pathway interac-
tions exist by calculating the corresponding empirical
p-value. For interaction between any pair of pathways,
firstly, count the number of permutations after which
the PPIs between the pair of permuted pathways is
higher than or equal to that of the pair of real pathways.
Secondly, divide the number by 1,000 which is the total
number of permutations and obtain the empirical p-value
of that interaction. All interactions with p < 0.05 are used
to construct the pathway network. (viii) Option: detect
CSPNs from phenotype-specific pathway networks. To
detect static CSPN, we firstly identify the common static
sub pathway network where nodes and edges appear at
each time point of each network, then identify highly
connected pathways in this sub pathway network. Along
with prior biological knowledge and the degree distribu-
tion of pathways in comprehensive pathway network,
part of these highly connected pathways and their
interactions could be detected as static CSPN. To detect
dynamic CSPN, at first, find pathways among which
interactions alter obviously, then, from found pathways,
further discover pathways which have relatively low
degrees in comprehensive pathway network. Along with
prior biological knowledge, part of these discovered
pathways and their interactions could be viewed as
dynamic CSPN.
Preparation of time course Microarray data
Since angiogenesis could be aroused by different
stimulus, the CSPNs for angiogenesis would be more
credible if more data about different stimulus were used.
Finally, two series of time course gene expression data,
GSE973 and GSE9055, about human umbilical vein
endothelial cells (HUVEC) after stimulations of IL-1 and
TNF-a were obtained from the Gene Expression Omni-
bus (GEO). GSE973 [16] has four samples: HUVEC were
stimulated with IL-1 for 0,0 . 5 ,1 ,2 . 5a n d6h o u r s ;
and GSE9055 [17] has twenty-five samples: Using
TNF-a, samples were collected every 15 min to arrays.
W es e l e c t e ds a m p l e so f0h1 5m ,1h1 5m ,3h1 5m ,
8 h 00 m of GSE9055 in order to compare these two
series appropriately. At each time point of these two
series, only one sample (microarray) is offered. Conse-
quently, we could not directly make use of coexpression
to infer active PPI at teach time point. Also, t test and
Bayesian analysis are not appropriate for discovering
differentially expressed genes. Finally, the differentially
expressed genes were obtained with fold change method.
Taking the quality of gene expression data and the
shortage of fold change method itself into account, we
should admit that genes with high expression level but
relatively small fold change may also reflect significant
biological meaning, even if their fold change values are
smaller than 2. Hence, we inferred that all the immediate
neighbours of those differentially expressed genes in the
PPI network were underlying relevant genes, for their
approved interactions with those differentially expressed
genes support the presumption of their relevance to
some extent. Then we considered those PPIs which have
at least one differentially expressed corresponding gene
as the active PPIs. Successively, we exploited this kind of
active interaction in construction of phenotype-specific
pathway network.
Figure 1
Workflow of construction of comprehensive pathway
network and detection of characteristic sub
pathway networks.
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Comprehensive pathway network construction
We first collected 48 pathways from ‘Environmental
Information Processing’ and ‘Cellular Processes’ cate-
gories of KEGG Pathway Maps. We identified 43 path-
ways which show significant enrichment in the list of
10204 genes involved in the generated PPI network. To
some extent, these 43 pathways have relatively high ratio
of proteins which have at least one interaction with other
proteins, which could explain why they are enriched in
the genes set of PPI network. Then a comprehensive
pathway network is constructed (Table 1 and Additional
file 1: Comprehensive pathway network) with 37 nodes
and 263 edges. Six pathways were not represented in this
network for their relatively higher independence in
comprehensive condition. It was possible that the PPIs
between these six pathways and other pathways were
relatively less in comprehensive condition but more in
specific case, or PPIs involved in these six pathways
mainly were inner-pathway PPIs.
Types of pathway interaction
To understand the cooperation of distinct pathways
more fully, all the five kinds of pathway interactions
were considered to form pathway networks (Table 2).
We made comparison between our perspective and other
two perspectives, which are only considering sharing
components, and only considering interactions exclud-
ing sharing components. In fact, when we only con-
sidered sharing components instead all five kinds of
interactions as the origin of crosstalk, the average degree
dropped. 76 interactions among 31 pathways were
removed, though 23 interactions involving 18 pathways
emerged. Interactions we lost are much more than
interactions came forth. When we considered interac-
tions excluding sharing components as the stem of
crosstalk, the average degree of pathway network
dropped observably and there were only 27 interactions
regarding 18 pathways.
Phenotype-specific pathway network construction
Using gene expression data of GSE973 and GSE9055, we
inferred relevant gene sets at each time points of both
series, and got two phenotype-specific pathway networks
for angiogenesis (Figure 2). One was of IL-1, and the
other was of TNF-a. Because no PPI is active in any case,
no pathway interaction always exists. Naturally, interac-
tions in both phenotype-specific pathway networks were
fewer than those in comprehensive pathway network
(Table 2) and some interactions altered over time. The
sub pathway network in IL-1 case, interactions within
which were constant over time, was approximately
Table 1: The top 16 Hub pathways (degree > 18) identified in Comprehensive pathway network
Abbreviation KEGG ID Pathway Name Degree
B cell has04662 B cell receptor signaling pathway 26
ErbB hsa04012 ErbB signaling pathway 26
FcERI hsa04664 Fc epsilon RI signaling pathway 26
VEGF hsa04370 VEGF signaling pathway 26
FA hsa04510 Focal adhesion 24
GnRH has04912 GnRH signaling pathway 24
Insulin hsa04910 Insulin signaling pathway 23
T cell hsa04660 T cell receptor signaling pathway 23
LtD hsa04720 Long-term potentiation 22
Pho hsa04070 Phosphatidylinositol signaling system 21
LtP hsa04730 Long-term depression 20
NKCMC hsa04650 Natural killer cell mediated cytotoxicity 20
ROAC hsa04810 Regulation of actin cytoskeleton 20
GJ hsa04540 Gap junction 19
MAPK hsa04010 MAPK signaling pathway 19
mTOR hsa04150 mTOR signaling pathway 19
Table 2: Comparison of degrees of different pathway networks
Pathway Network Number
of Nodes
Number
of Edges
Average
Degree
Comprehensive pathway network based on all types of pathway interactions 37 263 7.1
Comprehensive pathway network only based on sharing components 39 210 5.4
Comprehensive pathway network based on interactions without sharing components 18 27 1.5
Phenotype-specific pathway network in IL-1 case for angiogenesis, based on comprehensive pathway network 36 222 6.2
Phenotype-specific pathway network in TNF-a case for angiogenesis, based on comprehensive pathway network 41 241 5.9
Phenotype-specific pathway network in IL-1 case for angiogenesis, based on enriched pathway pipeline 10 15 1.5
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Phenotype (angiogenesis)-specific pathway network and characteristic sub pathway networks (CSPN).
A: Phenotype-specific pathway network in IL-1 case. B: Phenotype-specific pathway network in TNF-a case. C: Static
CSPN. D: Dynamic CSPN in IL-1 case. E: Dynamic CSPN in TNF-a case.
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pathways in IL-1 case, interactions among which altered
obviously over time, was nearly the same with its
counterpart in TNF-a case too, though the alterations
of pathway interactions in two cases were not identical.
Quality of pathway interacti o ni np h e n o t y p e - s p e c i f i c
pathway network
If we take into account the interactions among pathways
from a narrow perspective of enriched pathways, we will
miss important interactions. There are two typical
enriched pathway based approaches, both of which
have this problem [5,6]. Therefore, we argue that it is
more appropriate to construct pathway network for
relevant case through assessing the significance of
pathway interaction, no matter whether the pathways
are enriched in current case or not. Actually, this
approach is much better for comprehending the coop-
eration between distinct pathways, since the enrichment
analysis only reveals to which degree the whole but not
the relevant part of gene set of pathway takes part in
current case. We built a phenotype-specific pathway
network in IL-1 case based on enriched pathway pipeline
to illustrate its shortcoming (Table 2). There were only
15 interactions involving 10 pathways in this network.
Important interactions such as interaction between Wnt
and TGF-b signalling pathways disappeared.
Detecting CSPNs for angiogenesis
From two constructed phenotype-specific pathway
networks, static CSPN and dynamic CSPN for angiogen-
esis were detected. On the one hand, firstly, the common
static sub pathway network within which interactions
keep constant were identified. Then a part of this sub
network involving B cell receptor, T cell receptor, Toll-
like receptor, MAPK, VEGF and ErbB pathways was
detected as static CSPN (Figure 2). The high degrees of
those pathways and the almost full connected nature of
this part of network were maintained at each time point
in both cases. These pathways are highly connected in
comprehensive pathway network too, which means their
wide and deep involvement in different phenotypes.
Also, B cell receptor, T cell receptor and Toll-like receptor
signalling pathways are important in immunity; MAPK
pathway is involved in various cellular functions; VEGF
pathway is considered to be crucial in signal transduc-
tion in both physiologic and pathologic angiogenesis;
ErbB pathway couples binding of extracellular growth
factor ligands to intracellular signalling pathways reg-
ulating diverse biologic responses [13,18]. Therefore, we
derived that, conforming to interactions in the static
CSPN, pathways in static CSPN cooperated with each
other to receive, process and relay extracellular stimulus
for angiogenesis. On the other hand, there was another
group of pathways including TGF-b,W n t ,p 5 3p a t h w a y s
and cell cycle pathway, with interactions among them
was detected as dynamic CSPN (Figure 2). Actually,
those interactions changed observably over time in both
series. Their relatively low degrees in comprehensive
pathway interaction network might mean that they only
involved in specific phenotypes. In addition, these four
pathways all take part in the control of cell fate [13,19].
We inferred that the cooperation of them played a key
role in manifesting response of HUVEC to stimulus like
IL-1 and TNF-a via controlling development of HUVEC,
and reflected the phenotypic plasticity of HUVEC in
regard to angiogenesis.
In detail, interactions among pathways within static
CSPN are the immediate and constant response of
H U V E Ct ot h es t i m u l a t i o no fI L - 1o rT N F - a signal. The
B cell receptor, T cell receptor and Toll-like receptor
signalling pathways represented the innate immune
system to depress the excitement from stimulus [20].
They cooperated with each other to interfere with the
interactions among MAPK, ErbB and VEGF pathways,
which likely promoted angiogenesis [18,21,22]. Also,
within dynamic CSPN, p53 pathway was possibly
aroused to prevent angiogenesis via negatively regulating
cell cycle pathway [23]. But, cooperating with each other
to interact with cell cycle pathway, TGF-b and Wnt
pathways inside dynamic CSPN also were stirred up to
promote angiogenesis [24,25].
We compared the dynamic CSPN at each time point too
(Additional file 2: Comparison of dynamic CSPN at
different time points). In IL-1 case, p53 only interacted
with cell cycle pathway at second and fourth time points.
The first interaction might respond to the excitement
from static CSPN, since MAPK, ErbB and VEGF pathway
immediately cooperated with each other to promote
angiogenesis after treatment. The fourth interaction
probably reacted to the agitation from dynamic CSPN
itself, for TGF-b and Wnt pathways collaborated to
propel angiogenesis after the spread of signals from static
CSPN. Actually, Wnt pathway interacted with VEGF
pathway at the third time point (Additional file 3:
Pathway interaction at different time point(s) in IL-1
case), which likely invoked the collaboration between
Wnt and TGF-b pathways as well as their regulation to
cell cycle pathway. In TNF-a c a s e ,a tl a s tt h r e et i m e
points, p53 all interacted with cell cycle pathway, as well
as TGF-b and Wnt pathways cooperated to propel
angiogenesis by interacting with cell cycle pathway (see
Additional file 4). Virtually, all the interactions between
pathways within dynamic CSPN and pathways from
static CSPN were appeared after the first time point,
which possibly implied the transmission of signals from
static CSPN [23].
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CSPN between IL-1 case and TNF-a case probably
reflected the diversity of traits or dosages of stimulus,
though uncertainty of the cause remained before more
reliable data could be gathered for this pipeline. Also,
there was cooperation between static and dynamic
CSPNs. The static CSPN was likely the core one, because
of its immediate and sustained response to stimulus,
while the dynamic CSPN was probably the complemen-
tary one, by reason of its same effect to stimulus as the
static CSPN as well as the delay of its response. It is
reported that crosstalk of VEGF and Notch pathways is
crucial to tumor angiogenesis [26], resulting in blockade
of VEGF pathway sometimes doesn’t work [27]. In
angiogenesis of HUVEC, it is also possible that blocking
VEGF pathway make no effect for prevention of
angiogenesis, on account of the work of TGF-b and
Wnt pathways in dynamic CSPN.
Discussion
In this work, we mainly proposed a methodology to
consider the alteration of interactions among relevant
pathways for specific phenotype, and then to detect two
kinds CSPNs from constructed phenotype specific path-
way networks of different cases for the same certain
phenotype. We took angiogenesis on HUVEC as an
example. In the past years, many useful methods, which
could identify gene sets over-represented in biological
processes, were offered [2,3]. For example, LMMA
reconstructed the gene association network specific for
angiogenesis, and extracted significant pathways from
the network [3]. For moving forward to the next stage,
the interactions among pathways and the alterations of
these interactions require further investigation. Recently,
GPCN based [5] and PDS based [6] methods were
proposed to follow up this subject. But three problems
still existed: the types of interactions were lack in
consideration and discussion; the importance of context
needed to be taken into account; the alteration of
pathway interactions remained to be studied.
To solve these problems, we considered all five types
of pathway interactions to construct a comprehensive
pathway network, and inferred relevant genes of each
pathway and active PPIs with Microarray data. Then,
phenotype-specific pathway networks were constructed.
From these networks, alteration of pathway interactions
over time was distinct in each network, and alteration of
pathway interactions with different stimulus was clear
after comparison of corresponding networks. A static
CSPN and a dynamic CSPN were also detected from
these phenotype-specific pathway networks. The effect
and cooperating mechanism of distinct pathways within
both CSPNs, the influence of the diversity of traits or
dosages of stimulus to the evolvement of dynamic CSPN,
as well as the complementary role of dynamic CSPN to
static CSPN, were elaborated.
Actually, it will enhance the reliability of “active PPI” by
requiring corresponding genes firstly are coexpressed
within distinct case (series in GEO). We will go further in
the future to refine our work from this respect. In
addition, the detection of CSPNs for specific phenotype
requires ruling out the effect of other factors such as the
difference of stimulus and experimental bias. As a result,
the quantity and quality of corresponding time-course
microarray data are asked to be appropriate to obtain
reliable CSPNs. But now even the demand of quantity
can not be met. We also will go further in the future to
provide related active PPIs for each pathway interaction
and then predict the pathway interaction type.
Conclusion
The comprehensive pathway network helps us realize the
cooperative behaviour among pathways by providing
most of possible interactions among pathways. By
combining phenotype-specific gene expression data,
two kinds of potential CSPNs detected in this work,
the static CSPN and the dynamic CSPN, are helpful to
deeply understand the specific function and phenotypic
plasticity of angiogenesis.
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